Multiple sclerosis (MS) has long been known as a disease of immune dysregulation—where the body’s immune system mistakenly attacks its own brain and spinal cord. Interferon-β (IFN-β), one of the first disease-modifying therapies approved for MS, has been used for over 25 years to reduce relapses and delay disease progression. Yet, despite its success, scientists have never fully understood how IFN-β reshapes the immune system—or why some patients respond better than others.

A study by researchers at the University of Chicago, led by Dr. Xuan Feng and Dr. Anthony Reder, takes a deep look into this question. Using advanced multiplex assays and longitudinal data from over a decade of follow-up, they explored how IFN-β therapy reprograms immune signaling, both immediately and over years of treatment.

Their conclusion: IFN-β not only boosts antiviral and anti-inflammatory responses—it “rescues” a defective interferon system in MS, restoring immune balance and supporting neuroprotection.

The Core Problem: A Faulty Type I Interferon System
In untreated MS, immune signaling via type I interferons (IFN-α and IFN-β) is defective. Blood cells from people with MS show abnormally low levels of activated STAT1, a transcription factor that controls hundreds of antiviral and regulatory genes. This weak IFN response correlates with higher disease activity.

Environmental factors—like viral infections or vitamin D levels—can further modulate this pathway. Low vitamin D, for instance, weakens IFN signaling and promotes inflammatory Th1 immune responses, potentially worsening MS.

Study Design: Following Real Patients, in the Real World
The team followed 27 people with relapsing-remitting MS (RRMS) who had been on IFN-β therapy for almost 8 years. They were divided into two groups:

Complete Responders (CR): no relapses or progression for at least 5 years

Partial Responders (PR): experienced occasional relapses despite therapy

Blood samples were taken before and after IFN-β injections, and compared with those from therapy-naïve MS patients and healthy controls. The researchers measured 36 immune and neurotrophic proteins, as well as IFN-related signaling molecules (STAT1, MxA) and serum vitamin D.

Key Findings
1. IFN-β Restores a Broken Signaling Circuit
Before treatment, MS patients had abnormally low activity of p-S-STAT1, the key phosphorylated form of STAT1 that drives IFN-stimulated genes. After IFN-β injection, this signaling pathway reactivated—especially in partial responders. The therapy essentially “primed” immune cells to respond better to subsequent interferon exposure.

Interestingly, even after years of therapy, cells from PR patients responded more strongly than those from CRs, suggesting that higher baseline IFN activity predicts weaker long-term clinical response. In contrast, CRs had very low endogenous IFN levels but benefited most clinically.

2. Serum Interferon Activity Predicts Disease Course
After temporarily stopping therapy (“washout”), serum type I IFN activity was 18-fold higher in PR than CR.

CRs had very low baseline IFN levels—yet were relapse-free.

PRs had higher baseline IFN—yet continued to relapse occasionally.

This pattern mirrors other autoimmune diseases: lupus and neuromyelitis optica (NMO) both show excessive IFN activity that worsens inflammation. In MS, a mild IFN deficiency appears protective, while excessive activation may be counterproductive.

3. Short-Term IFN-β Injections Shift Immunity Toward Repair
A single IFN-β injection triggered:

Anti-inflammatory (Th2) cytokines: IL-4, IL-10, IL-12p40

Reduced pro-inflammatory (Th1) cytokines: IL-7, IL-12p70

Increased neurotrophic factors: BDNF, CNTF, HGF during relapses
These molecules support neuronal survival, synaptic repair, and remyelination—suggesting that IFN-β may directly foster neuroprotection beyond immune modulation.

4. Long-Term Therapy Rebalances the Immune Network
In untreated MS, cytokine levels were surprisingly low and poorly correlated, showing a disordered immune system.

After years on IFN-β therapy, patients’ cytokine profiles became strongly inter-correlated—a hallmark of a balanced immune state, similar to that of healthy individuals.

This “re-synchronization” of immune signaling may explain why long-term IFN-β use leads to fewer relapses, less MRI activity, and reduced mortality decades later.

5. Vitamin D Enhances the IFN Response
Vitamin D and IFN-β appear to work hand-in-hand. In patients with higher serum vitamin D, IFN-β responses were stronger and more balanced:

In PR, vitamin D correlated with both Th1 and Th2 cytokines.

In CR, vitamin D was linked mainly to anti-inflammatory responses.

These findings underscore the potential benefit of maintaining optimal vitamin D levels in people with MS undergoing IFN therapy.

Why This Matters
This study reframes IFN-β not just as a drug that suppresses inflammation—but as a restorative therapy that recalibrates a malfunctioning immune system.

It also challenges the idea that more immune activation is always better. In MS, less may be more: patients with lower baseline IFN activity seem to achieve more stable disease control.

Finally, the integration of immune, molecular, and neurotrophic data highlights how MS treatments can influence both the immune system and the brain’s repair machinery.

Conclusions: A Restored Balance
IFN-β corrects defective interferon signaling and low serum IFN levels in MS.

It enhances immune regulation, reduces Th1 inflammation, and promotes Th2 and neuroprotective pathways.

Long-term therapy re-establishes immune harmony, resembling healthy immune dynamics.

Low baseline IFN levels and strong Th2 responses predict better long-term outcomes.

As Dr. Reder’s team notes, “Correction of immune disruption suggests new mechanisms for immunopathology and therapy.” This research may help refine future treatment strategies—not only for MS but also for related autoimmune and neuroinflammatory disorders.

Disclaimer: This blog post is based on the information provided in the cited scientific article. It aims to provide an accessible summary of the research findings and should not be considered as definitive medical advice. For any health concerns, please consult with a qualified healthcare professional.

Reference:
Li L, Olcer M, Wang Z, Song Y, Ke J, Feng X, Reder AT. (2025). IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses. PLOS One, 20(9): e0330867. https://doi.org/10.1371/journal.pone.0330867